OOIR: Observatory of International Research

Papers

(The H4-Index of CTS-Clinical and Translational Science is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear	267
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?	125
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration	113
SARS‐CoV‐2 infection as a trigger of autoimmune response	105
Opportunities and challenges in translational science	78
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation	54
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	52
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial	51
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	50
Approval success rates of drug candidates based on target, action, modality, application, and their combinations	49
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial	40
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs	40
Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm	40
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	38
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH	37
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel	35
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence	34
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction	32
Artificial intelligence in pharmacology research and practice	32
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor	32
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events	30
A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study	30
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	29
Drugs used for the treatment of cerebral and disseminated infections caused by free‐living amoebae	29
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study	29

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)	29
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV	27
Artificial intelligence in rare disease diagnosis and treatment	27
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults	27
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	27